NO20043022L - 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister - Google Patents

5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister

Info

Publication number: NO20043022L
Authority: NO; Norway
Prior art keywords: diaryl; pyrazine; antagonists; amide derivatives; amide
Prior art date: 2001-12-19

Application number

NO20043022A

Other languages

English (en)

Inventor

Stig Jonas Bostrom

Anna Ingrid Kristina Berggren

Stig Thomas Elebring

Peter Greasley

Emma Terricabra

Johan Michael Wilstermann

Original Assignee

Astrazeneca Ab Global Ip

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-19

Filing date

2004-07-15

Publication date

2004-07-15

2004-07-15 Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip

2004-07-15 Publication of NO20043022L publication Critical patent/NO20043022L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Cardiology (AREA)
Addiction (AREA)
Vascular Medicine (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20043022A 2001-12-19 2004-07-15 5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister NO20043022L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE0104330A SE0104330D0 (sv)	2001-12-19	2001-12-19	Therapeutic agents
PCT/GB2002/005742 WO2003051851A1 (en)	2001-12-19	2002-12-18	5, 6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists

Publications (1)

Publication Number	Publication Date
NO20043022L true NO20043022L (no)	2004-07-15

Family

ID=20286429

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20043022A NO20043022L (no)	2001-12-19	2004-07-15	5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister

Country Status (25)

Country	Link
US (1)	US7342019B2 (no)
EP (1)	EP1458690B1 (no)
JP (1)	JP2005517655A (no)
KR (1)	KR20040068286A (no)
CN (1)	CN1620438A (no)
AR (1)	AR038044A1 (no)
AT (1)	ATE354570T1 (no)
AU (1)	AU2002352425A1 (no)
BR (1)	BR0214989A (no)
CA (1)	CA2469786A1 (no)
CO (1)	CO5590917A2 (no)
DE (1)	DE60218340T2 (no)
ES (1)	ES2280599T3 (no)
HU (1)	HUP0402026A3 (no)
IL (1)	IL162377A0 (no)
IS (1)	IS7314A (no)
MX (1)	MXPA04005990A (no)
NO (1)	NO20043022L (no)
NZ (1)	NZ533275A (no)
PL (1)	PL369731A1 (no)
RU (1)	RU2004116916A (no)
SE (1)	SE0104330D0 (no)
TW (1)	TW200410694A (no)
WO (1)	WO2003051851A1 (no)
ZA (1)	ZA200404805B (no)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7704995B2 (en)	2002-05-03	2010-04-27	Exelixis, Inc.	Protein kinase modulators and methods of use
GB0216700D0 (en)	2002-07-18	2002-08-28	Astrazeneca Ab	Process
WO2004029204A2 (en)	2002-09-27	2004-04-08	Merck & Co., Inc.	Substituted pyrimidines
US7129239B2 (en)	2002-10-28	2006-10-31	Pfizer Inc.	Purine compounds and uses thereof
US7247628B2 (en)	2002-12-12	2007-07-24	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
GB0230088D0 (en) *	2002-12-24	2003-01-29	Astrazeneca Ab	Therapeutic agents
GB0302671D0 (en) *	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
GB0302673D0 (en)	2003-02-06	2003-03-12	Astrazeneca Ab	Pharmaceutical formulations
US7176210B2 (en)	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7141669B2 (en)	2003-04-23	2006-11-28	Pfizer Inc.	Cannabiniod receptor ligands and uses thereof
US7145012B2 (en)	2003-04-23	2006-12-05	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
US7268133B2 (en)	2003-04-23	2007-09-11	Pfizer, Inc. Patent Department	Cannabinoid receptor ligands and uses thereof
US7232823B2 (en)	2003-06-09	2007-06-19	Pfizer, Inc.	Cannabinoid receptor ligands and uses thereof
WO2004111033A1 (en) *	2003-06-18	2004-12-23	Astrazeneca Ab	2-substitued 5, 6-diaryl-pyrazine derivatives as cb1 modulator.
GB0314049D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314057D0 (en) *	2003-06-18	2003-07-23	Astrazeneca Ab	Therapeutic agents
GB0314261D0 (en) *	2003-06-19	2003-07-23	Astrazeneca Ab	Therapeutic agents
EP1644335A4 (en)	2003-07-11	2008-06-04	Bristol Myers Squibb Co	TETRAHYDROQUINOLINE DERIVATIVES COMPRISING MODULATORS OF CANNABINOID RECEPTORS
US7326706B2 (en)	2003-08-15	2008-02-05	Bristol-Myers Squibb Company	Pyrazine modulators of cannabinoid receptors
EP1663215A1 (en) *	2003-09-02	2006-06-07	Solvay Pharmaceuticals GmbH	Novel medical use of selective cb1- receptor antagonists
US7320805B2 (en) *	2003-10-01	2008-01-22	Institut National De La Sante Et De La Recherche Medicale	CB2 receptors blocks accumulation of human hepatic myofibroblasts: a novel artifibrogenic pathway in the liver
US7517900B2 (en)	2003-10-10	2009-04-14	Bristol-Myers Squibb Company	Pyrazole derivatives as cannabinoid receptor modulators
TW200528102A (en) *	2003-10-24	2005-09-01	Solvay Pharm Gmbh	Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2005039579A1 (en) *	2003-10-24	2005-05-06	Solvay Pharmaceuticals Gmbh	Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors
GB0327331D0 (en) *	2003-11-25	2003-12-31	Astrazeneca Ab	Therapeutic agents
EP1734963A4 (en)	2004-04-02	2008-06-18	Merck & Co Inc	METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
TW200602314A (en)	2004-05-28	2006-01-16	Tanabe Seiyaku Co	A novel pyrrolidine compound and a process for preparing the same
EP1807063A2 (en)	2004-10-25	2007-07-18	Solvay Pharmaceuticals GmbH	Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
DK1868999T3 (da)	2005-04-06	2009-08-17	Hoffmann La Roche	Pyridin-3-carboxamidderivater som omvendte CB1-agonister
US20070078135A1 (en) *	2005-04-18	2007-04-05	Neurogen Corporation	Substituted heteroaryl CB1 antagonists
AU2006264649A1 (en)	2005-06-30	2007-01-11	Prosidion Limited	GPCR agonists
US7629346B2 (en)	2006-06-19	2009-12-08	Hoffmann-La Roche Inc.	Pyrazinecarboxamide derivatives as CB1 antagonists
US7781593B2 (en)	2006-09-14	2010-08-24	Hoffmann-La Roche Inc.	5-phenyl-nicotinamide derivatives
MX2009003222A (es) *	2006-10-04	2009-04-06	Hoffmann La Roche	Derivados de 3-piridinocarboxamida y 2-pirazinocarboxamida como agentes elevadores de colesterol de lipoproteina de alta densidad.
AR064735A1 (es)	2007-01-04	2009-04-22	Prosidion Ltd	Agonistas de gpcr y composicion farmaceutica en base al compuesto
GB0700122D0 (en)	2007-01-04	2007-02-14	Prosidion Ltd	GPCR agonists
PE20081849A1 (es)	2007-01-04	2009-01-26	Prosidion Ltd	Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr
PT2114933E (pt)	2007-01-04	2011-12-20	Prosidion Ltd	Agonistas do gpcr de piperidina
JP2010514832A (ja)	2007-01-04	2010-05-06	プロシディオン・リミテッド	ピペリジンｇｐｃｒアゴニスト
GB0720389D0 (en)	2007-10-18	2008-11-12	Prosidion Ltd	G-Protein Coupled Receptor Agonists
GB0720390D0 (en)	2007-10-18	2007-11-28	Prosidion Ltd	G-Protein coupled receptor agonists
WO2010079241A1 (es)	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US8410107B2 (en)	2010-10-15	2013-04-02	Hoffmann-La Roche Inc.	N-pyridin-3-yl or N-pyrazin-2-yl carboxamides
US8669254B2 (en)	2010-12-15	2014-03-11	Hoffman-La Roche Inc.	Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents
US9403808B2 (en) *	2011-10-28	2016-08-02	Hoffmann-La Roche Inc.	Pyrazine derivatives
US12036292B2 (en)	2020-08-06	2024-07-16	Chdi Foundation, Inc.	Heterobiaryl compounds and imaging agents for imaging huntingtin protein
WO2024159284A1 (pt) *	2023-01-30	2024-08-08	Eurofarma Laboratórios S.A.	Hidrazidas bloqueadoras de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits
WO2024159286A1 (pt) *	2023-01-30	2024-08-08	Eurofarma Laboratórios S.A.	Compostos fenólicos bloqueadores de nav 1.7 e/ou nav 1.8, seus processos de obtenção, composições, usos, métodos de tratamento destes e kits

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH458361A (de)	1965-01-15	1968-06-30	Eprova Ag	Verfahren zur Herstellung von Pyrazincarbonsäuren
JPS5322529A (en) *	1976-08-13	1978-03-02	Nippon Soda Co Ltd	Dihydropyrazine derivative and its preparation
WO1989004308A1 (en)	1987-11-12	1989-05-18	Terumo Kabushiki Kaisha	Pyrazine derivatives and medicinal preparation containing same
JPH06501926A (ja)	1990-08-06	1994-03-03	藤沢薬品工業株式会社	複素環式化合物
FR2713225B1 (fr) *	1993-12-02	1996-03-01	Sanofi Sa	N-pipéridino-3-pyrazolecarboxamide substitué.

2001
- 2001-12-19 SE SE0104330A patent/SE0104330D0/xx unknown
2002
- 2002-12-18 US US10/499,054 patent/US7342019B2/en not_active Expired - Fee Related
- 2002-12-18 CN CNA028281535A patent/CN1620438A/zh active Pending
- 2002-12-18 AU AU2002352425A patent/AU2002352425A1/en not_active Abandoned
- 2002-12-18 MX MXPA04005990A patent/MXPA04005990A/es unknown
- 2002-12-18 EP EP02788143A patent/EP1458690B1/en not_active Expired - Lifetime
- 2002-12-18 CA CA002469786A patent/CA2469786A1/en not_active Abandoned
- 2002-12-18 WO PCT/GB2002/005742 patent/WO2003051851A1/en active IP Right Grant
- 2002-12-18 RU RU2004116916/04A patent/RU2004116916A/ru not_active Application Discontinuation
- 2002-12-18 KR KR10-2004-7009589A patent/KR20040068286A/ko not_active Application Discontinuation
- 2002-12-18 PL PL02369731A patent/PL369731A1/xx not_active Application Discontinuation
- 2002-12-18 AT AT02788143T patent/ATE354570T1/de not_active IP Right Cessation
- 2002-12-18 HU HU0402026A patent/HUP0402026A3/hu unknown
- 2002-12-18 ES ES02788143T patent/ES2280599T3/es not_active Expired - Lifetime
- 2002-12-18 JP JP2003552736A patent/JP2005517655A/ja active Pending
- 2002-12-18 BR BR0214989-3A patent/BR0214989A/pt not_active IP Right Cessation
- 2002-12-18 IL IL16237702A patent/IL162377A0/xx unknown
- 2002-12-18 DE DE60218340T patent/DE60218340T2/de not_active Expired - Fee Related
- 2002-12-18 NZ NZ533275A patent/NZ533275A/en unknown
- 2002-12-19 AR ARP020105001A patent/AR038044A1/es not_active Application Discontinuation
- 2002-12-19 TW TW091136671A patent/TW200410694A/zh unknown
2004
- 2004-06-16 IS IS7314A patent/IS7314A/is unknown
- 2004-06-17 ZA ZA200404805A patent/ZA200404805B/en unknown
- 2004-07-09 CO CO04065292A patent/CO5590917A2/es not_active Application Discontinuation
- 2004-07-15 NO NO20043022A patent/NO20043022L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CN1620438A (zh)	2005-05-25
WO2003051851A1 (en)	2003-06-26
TW200410694A (en)	2004-07-01
MXPA04005990A (es)	2004-09-27
NZ533275A (en)	2006-02-24
ATE354570T1 (de)	2007-03-15
JP2005517655A (ja)	2005-06-16
HUP0402026A2 (hu)	2005-02-28
BR0214989A (pt)	2004-12-14
RU2004116916A (ru)	2005-11-10
CA2469786A1 (en)	2003-06-26
IS7314A (is)	2004-06-16
US20050032808A1 (en)	2005-02-10
AU2002352425A1 (en)	2003-06-30
HUP0402026A3 (en)	2005-08-29
DE60218340D1 (de)	2007-04-05
ES2280599T3 (es)	2007-09-16
EP1458690A1 (en)	2004-09-22
IL162377A0 (en)	2005-11-20
ZA200404805B (en)	2005-08-15
AR038044A1 (es)	2004-12-22
CO5590917A2 (es)	2005-12-30
EP1458690B1 (en)	2007-02-21
DE60218340T2 (de)	2007-11-29
US7342019B2 (en)	2008-03-11
PL369731A1 (en)	2005-05-02
SE0104330D0 (sv)	2001-12-19
KR20040068286A (ko)	2004-07-30

Publication	Publication Date	Title
NO20043022L (no)	2004-07-15	5,6-diaryl-pyrazin-2-amid-derivater som CB1-antagonister
DE60216115D1 (de)	2006-12-28	BENZIMIDAZO 4,5-föISOCHINOLINON-DERIVATE
DK1429761T3 (da)	2007-02-05	Hidtil ukendte 4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
CY2014041I1 (el)	2016-07-27	2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
NO20032892L (no)	2003-11-18	4,5-dihydro-1H-pyrazolderivater med CB1-antagonistisk virkning
DE60214428D1 (de)	2006-10-12	1, 4-dihydro-1, 4-diphenylpyridin-derivate
DE50210707D1 (de)	2007-09-27	Substituierte 2-pyridin-cyclohexan-1,4-diaminderivate
DK1379522T3 (da)	2005-05-30	Dihydro-benzo(b)(1,4)diazeping-2-on-derivater som MGLUR2-antagonister I
DE60225563D1 (de)	2008-04-24	4-amino-6-phenyl-pyrroloä2,3-düpyrimidin derivate
NO20041560L (no)	2004-05-11	1,6-nafthyridinderivater som antidiabetiske midler
DE60205100D1 (de)	2005-08-25	DIHYDRO-BENZO (b) (1,4) DIAZEPIN-2-ON-DERIVATE ALS MGLUR2 ANTAGONISTEN
DK1414803T3 (da)	2013-03-25	Pyrazolylcarboxanilider som fungicider
NO20023485L (no)	2002-09-03	1,3-disubstituerte pyrrolidiner som alfa-2- adrenoceptorantagonister
NO20041075L (no)	2004-03-15	Ny 1, 2, 4-triazolforbindelse
DE60203696D1 (de)	2005-05-19	Härtbare, schweissbare überzugszusammensetzungen
DE602004021572D1 (de)	2009-07-30	SUBSTITUIERTE 8-PERFLUORO-6,7,8,9-TETRAHYDROPYRIMIDOi1,2-A PYRIMIDIN-4-ON-DERIVATE
MXPA03006991A (es)	2003-11-18	Derivados de piperidina como antagonistas de neurocinina 1.
ATE326467T1 (de)	2006-06-15	Imidazo 1,2-aöpyridine
DE50107988D1 (de)	2005-12-15	Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
NO20021251D0 (no)	2002-03-13	Tienoisoksazolyl- og tienylpyrrazolyl-fenoksysubstituerte propylderivater anvendelige som D4antagonister
DE60224221D1 (de)	2008-01-31	Aminotetralinderivate, antagonisten von muscarinrezeptoren
NO20042980L (no)	2004-07-14	3,4-dihydro-1H-isokinolin-2-yl-derivater
DE60315471D1 (de)	2007-09-20	2,5-disubstituierte 3-mercaptopentansaure
NO20044405L (no)	2004-10-15	Neurotensinaktive 2,3-diaryl-pyrazolidin derivater
IS7131A (is)	2004-01-29	Nýjar 2,4-díamínóþíasól afleiður

Legal Events

Date	Code	Title	Description
2007-08-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application